Page last updated: 2024-11-02

pamidronate and Metastase

pamidronate has been researched along with Metastase in 20 studies

Research Excerpts

ExcerptRelevanceReference
"To assess whether pamidronate can reduce the frequency of skeletal morbidity in women with lytic bone metastases from breast cancer treated with hormone therapy."9.09Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group. ( Costello, S; Glück, S; Heffernan, M; Hortobagyi, GN; Kennedy, I; Knight, RD; Leff, R; Lipton, A; Mellars, K; Reitsma, DJ; Seaman, JJ; Simeone, J; Stewart, JF; Theriault, RL, 1999)
" generic pamidronate in female breast cancer patients with metastatic bone disease, undergoing i."7.73Cost-effectiveness of oral ibandronate compared with intravenous (i.v.) zoledronic acid or i.v. generic pamidronate in breast cancer patients with metastatic bone disease undergoing i.v. chemotherapy. ( Barrett-Lee, P; Body, JJ; Canney, P; De Cock, E; Hutton, J; Lewis, G; Neary, MP, 2005)
"In a cross-sectional study, 24-h urinary excretion of pamidronate and the biochemical marker of bone resorption N-terminal telopeptide of type 1 collagen and serum alkaline phosphatase were measured in 40 patients with bone metastases from breast cancer at the beginning, after 3-6 months, and after 1 year of treatment with intravenous pamidronate 90 mg every 3-4 weeks."7.73Skeletal retention of bisphosphonate (pamidronate) and its relation to the rate of bone resorption in patients with breast cancer and bone metastases. ( Cremers, SC; den Hartigh, J; Gelderblom, H; Papapoulos, SE; Seynaeve, C; van der Rijt, CC; van Zuylen, L; Vermeij, P, 2005)
" This model was applied to the placebo-control arm of a pamidronate study in patients with malignant bone disease from breast cancer."5.14Natural history of malignant bone disease in breast cancer and the use of cumulative mean functions to measure skeletal morbidity. ( Coleman, RE; Cook, RJ; Lipton, A; Major, PP; Smith, MR; Terpos, E, 2009)
"To assess whether pamidronate can reduce the frequency of skeletal morbidity in women with lytic bone metastases from breast cancer treated with hormone therapy."5.09Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group. ( Costello, S; Glück, S; Heffernan, M; Hortobagyi, GN; Kennedy, I; Knight, RD; Leff, R; Lipton, A; Mellars, K; Reitsma, DJ; Seaman, JJ; Simeone, J; Stewart, JF; Theriault, RL, 1999)
"Zoledronic acid seems to be the most efficacious bisphosphonate for reducing the risk of SREs in patients with cancer of the breast or prostate and those with multiple myeloma."4.89Comparative efficacy of bisphosphonates in metastatic breast and prostate cancer and multiple myeloma: a mixed-treatment meta-analysis. ( Brown, J; Fullarton, JR; Palmieri, C, 2013)
" generic pamidronate in female breast cancer patients with metastatic bone disease, undergoing i."3.73Cost-effectiveness of oral ibandronate compared with intravenous (i.v.) zoledronic acid or i.v. generic pamidronate in breast cancer patients with metastatic bone disease undergoing i.v. chemotherapy. ( Barrett-Lee, P; Body, JJ; Canney, P; De Cock, E; Hutton, J; Lewis, G; Neary, MP, 2005)
"In a cross-sectional study, 24-h urinary excretion of pamidronate and the biochemical marker of bone resorption N-terminal telopeptide of type 1 collagen and serum alkaline phosphatase were measured in 40 patients with bone metastases from breast cancer at the beginning, after 3-6 months, and after 1 year of treatment with intravenous pamidronate 90 mg every 3-4 weeks."3.73Skeletal retention of bisphosphonate (pamidronate) and its relation to the rate of bone resorption in patients with breast cancer and bone metastases. ( Cremers, SC; den Hartigh, J; Gelderblom, H; Papapoulos, SE; Seynaeve, C; van der Rijt, CC; van Zuylen, L; Vermeij, P, 2005)
" In conclusion, RT combined with BMA was found to be more effective than BMA alone for the treatment of osteolytic bone metastasis, which thereby improves the prognosis."1.56Radiation therapy combined with bone-modifying agents ameliorates local control of osteolytic bone metastases in breast cancer. ( Kajima, M; Makita, C; Manabe, Y; Matsuo, M; Matsuyama, K; Tanaka, H, 2020)
"For patients with HCM who do not achieve a response from bisphosphonates, or for those who need repeated dosing more often than expected, changing to a different drug class could be an alternative."1.35A case of resistant hypercalcemia of malignancy with a proposed treatment algorithm. ( Linneman, T; McMahan, J, 2009)
"The various features of carcinoid tumors metastasizing to the skeleton are briefly reviewed."1.31Case of an ivory vertebra. ( Ball, DW; Basaria, S; Belzberg, AJ; McCarthy, EF, 2000)
" No significant increase in the median survival time of tumor-bearing animals was achieved at the two dosage schemes tested, i."1.27Distribution of 3-amino-1-hydroxypropane-1,1-diphosphonic acid in rats and effects on rat osteosarcoma. ( Schmähl, D; Wingen, F, 1985)

Research

Studies (20)

TimeframeStudies, this research(%)All Research%
pre-19901 (5.00)18.7374
1990's3 (15.00)18.2507
2000's11 (55.00)29.6817
2010's4 (20.00)24.3611
2020's1 (5.00)2.80

Authors

AuthorsStudies
Tanaka, H1
Makita, C1
Manabe, Y1
Kajima, M1
Matsuyama, K1
Matsuo, M1
Hahn, NM1
Yiannoutsos, CT1
Kirkpatrick, K1
Sharma, J1
Sweeney, CJ1
Palmieri, C1
Fullarton, JR1
Brown, J1
Addison, CL1
Bouganim, N1
Hilton, J1
Vandermeer, L1
Dent, S1
Amir, E1
Hopkins, S1
Kuchuk, I1
Segal, R1
Song, X1
Gertler, S1
Mazzarello, S1
Dranitsaris, G1
Ooi, D1
Pond, G1
Clemons, M1
McMahan, J1
Linneman, T1
Major, PP1
Cook, RJ1
Lipton, A2
Smith, MR1
Terpos, E1
Coleman, RE1
Ngamphaiboon, N1
Frustino, JL1
Kossoff, EB1
Sullivan, MA1
O'Connor, TL1
El-Abdaimi, K1
Ste-Marie, LG1
Papavasiliou, V1
Dion, N1
Cardinal, PE1
Huang, D1
Kremer, R1
Wenzel, C1
Bartsch, R1
Hussian, D1
Pluschnig, U1
Locker, GJ1
Sevelda, U1
Zielinski, CC1
Steger, GG1
De Cock, E1
Hutton, J1
Canney, P1
Body, JJ1
Barrett-Lee, P1
Neary, MP1
Lewis, G1
Liauw, W1
Segelov, E1
Lih, A1
Dunleavy, R1
Links, M1
Ward, R1
Cremers, SC1
Papapoulos, SE1
Gelderblom, H1
Seynaeve, C1
den Hartigh, J1
Vermeij, P1
van der Rijt, CC1
van Zuylen, L1
Sauter, M1
Jülg, B1
Porubsky, S1
Cohen, C1
Fischereder, M1
Sitter, T1
Schlondorff, D1
Gröne, HJ1
Boissier, S1
Magnetto, S1
Frappart, L1
Cuzin, B1
Ebetino, FH1
Delmas, PD1
Clezardin, P1
Theriault, RL1
Hortobagyi, GN1
Leff, R1
Glück, S1
Stewart, JF1
Costello, S1
Kennedy, I1
Simeone, J1
Seaman, JJ1
Knight, RD1
Mellars, K1
Heffernan, M1
Reitsma, DJ1
Basaria, S1
McCarthy, EF1
Belzberg, AJ1
Ball, DW1
Johnston, SR1
Korfel, A1
Fischer, L1
Foss, HD1
Koch, HC1
Thiel, E1
Clarke, NW1
Holbrook, IB1
McClure, J1
George, NJ1
Wingen, F1
Schmähl, D1

Clinical Trials (2)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Ability of Risedronate to Prevent Skeletal Related Events in Patients With Metastatic Prostate Cancer Commencing Hormonal Therapy: Hoosier Oncology Group GU02-41[NCT00216060]Phase 363 participants (Actual)Interventional2003-10-31Terminated (stopped due to Terminated due to low accrual)
Bone Retention of Bisphosphonate (Zometa) in Patients With Multiple Myeloma or Breast Cancer With Metastases to Bone[NCT00760370]Phase 260 participants (Actual)Interventional2008-12-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Numbers of SRE or Death Occurred Cumulatively

Number of participants experiencing a SRE(skeletal-related event) or death occurred, cumulative from each arm ( a daily oral dose of 30 mg risedronate, or placebo) (NCT00216060)
Timeframe: 36 months

Interventionparticipants (Number)
Risedronate Arm11
Placebo Arm13

Rate of Patients Archiving a PSA (Prostate Specific Antigen) Nadir < 0.2 ng/mL

(NCT00216060)
Timeframe: 36 months

Interventionpercentage of participants (Number)
Risedronate Arm50
Placebo Arm29

Three- Year Survival Rate

(NCT00216060)
Timeframe: 36 months

Interventionpercentage of participants (Number)
Risedronate72.5
Placebo71.5

Bone Turnover Marker Changes -- Urine Total Deoxypyridinoline (DPD)

"Urine total DPD median in response to treatment on both study arms at week 24. compare median from baseline and week 24.~Deoxypyridinoline (DPD) is measured in hydrolyzed urine samples using high-performance liquid chromatography technique. After extraction of the cross-links and elimination of the urine impurities by a Bio-Rad SPE cartridge (Bio-Rad Laboratories, Hercules, CA), total DPD is eluted from reverse-phase high-performance liquid chromatography by ion pair chromatography with isocratic elution.~The compounds are detected as a result of their natural fluorescence with a fluorescence detector" (NCT00216060)
Timeframe: 24 weeks

,
Interventionnmol/mmol creatinine (Median)
week 24baseline
Placebo Arm12.6210.12
Risedronate Arm6.918.83

Bone Turnover Marker Changes-- Serum BAP

Serum BAP median changes between baseline and week 24. The Ostase assays are performed with an access immunoassay system, which is an assay of serum samples that provides a quantitative measurement of bone alkaline phosphatase (BAP). A mouse monoclonal antibody specific to BAP is added to a re-action vessel with paramagnetic particles coated with goat antimouse polyclonalantibody.Calibrators,controls,andsamplescontainingBAP are added to the coated particles and bind to the anti-BAP monoclonal antibody. After the formation of a solid phase/capture antibody/BAP complex, separation in a magnetic field and washing remove materials not bound to the solid phase. A chemiluminescent substrate, LumiPhos 530, is added to the reaction vessel, and light generated by the reaction is measured with a luminometer. The light production is directly proportional to the concentration of BAP in the sample. The amount of analyte in thesample is determined from a stored multipoint calibration curve (NCT00216060)
Timeframe: 24 week

,
Interventionng/mL (Median)
24 weekbaseline
Placebo Arm13.1619.50
Risedronate Arm9.520.95

Bone Turnover Marker Changes-- Serum Osteocalcin (OC)

Serum Osteocalcin (OC) medians between baseline and 24 weeks areperformed with the Elecsys 2010 automated analyzer, which uses an electrochemiluminescence immunoassay technique for the in vitro quantitative determination of serum total osteocalcin in humanserum. The assay uses a sandwich test principle in which afirst biotinylated monoclonal antibody recognizing N-MID osteocalcin and a second monoclonal antibody against N-MID osteocalcin labeled with ruthenium are incubated with 20mL of serum. After a first incubation, streptavidin-coated microparticles are added for a second incubation, and the complex becomes bound to the solid phase by interaction of biotin and streptavidin.These microparticles are then magnetically captured onto the surface of an electrode. Application of a voltage on this electrode induces chemiluminescent emission, which is measured by a photomultiplierand compared with a calibration curve that is generated in aninstrument-specific manner by 2-point calibration. (NCT00216060)
Timeframe: 24 week

,
Interventionug/L (Median)
at 24 weekbaseline
Placebo Arm27.3518.24
Risedronate Arm11.8820.08

Bone Turnover Marker Changes-- Urine N-telopeptide (NTX) Median

"Urine N-telopeptide (NTX) median changes between baseline and week 24. The assays are performed with the NTx Reagent Pack kit from Ortho-Clinical Diagnostics (Ortho-Clinical Diagnostics/Johnson & Johnson, Amersham, UK), which is a kit designed for the quantitative determination of N-terminal telopeptide (NTx) in human urine on the automated Vitros Immunodiagnostic System ECi (Ortho-Clinical Diagnostics/Johnson & Johnson, Amersham, UK). A competitive immunoassay technique is used. This depends on competition between NTx present in the sample and a synthetic NTx peptide coated on the wells for binding by a horseradish peroxidase (HRP)-labeled antibody conjugate (mouse monoclonal anti-NTx). The conjugate is captured by the peptide coated on the wells; unbound materials are removed by washing.~The bound HRP conjugate is measured by a luminescent reaction." (NCT00216060)
Timeframe: 24 week

,
Interventionnmol BCE/mmol creatinine (Median)
at 24 weekbaseline
Placebo Arm62.9548.08
Risedronate Arm20.6341.33

Reviews

2 reviews available for pamidronate and Metastase

ArticleYear
Comparative efficacy of bisphosphonates in metastatic breast and prostate cancer and multiple myeloma: a mixed-treatment meta-analysis.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2013, Dec-15, Volume: 19, Issue:24

    Topics: Breast Neoplasms; Clodronic Acid; Diphosphonates; Female; Humans; Ibandronic Acid; Imidazoles; Male;

2013
Systemic treatment of metastatic breast cancer.
    Hospital medicine (London, England : 1998), 2001, Volume: 62, Issue:5

    Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Aromatase Inh

2001

Trials

5 trials available for pamidronate and Metastase

ArticleYear
Failure to suppress markers of bone turnover on first-line hormone therapy for metastatic prostate cancer is associated with shorter time to skeletal-related event.
    Clinical genitourinary cancer, 2014, Volume: 12, Issue:1

    Topics: Aged; Alkaline Phosphatase; Amino Acids; Androgen Antagonists; Antibodies, Monoclonal, Humanized; Bi

2014
A phase II, multicentre trial evaluating the efficacy of de-escalated bisphosphonate therapy in metastatic breast cancer patients at low-risk of skeletal-related events.
    Breast cancer research and treatment, 2014, Volume: 144, Issue:3

    Topics: Administration, Intravenous; Biomarkers; Bone Density Conservation Agents; Bone Neoplasms; Breast Ne

2014
Natural history of malignant bone disease in breast cancer and the use of cumulative mean functions to measure skeletal morbidity.
    BMC cancer, 2009, Aug-06, Volume: 9

    Topics: Adult; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; H

2009
Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1999, Volume: 17, Issue:3

    Topics: Adolescent; Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Disea

1999
Osteoclast inhibition by pamidronate in metastatic prostate cancer: a preliminary study.
    British journal of cancer, 1991, Volume: 63, Issue:3

    Topics: Aged; Aged, 80 and over; Biomarkers, Tumor; Bone and Bones; Diphosphonates; Humans; Hydroxyproline;

1991

Other Studies

13 other studies available for pamidronate and Metastase

ArticleYear
Radiation therapy combined with bone-modifying agents ameliorates local control of osteolytic bone metastases in breast cancer.
    Journal of radiation research, 2020, May-22, Volume: 61, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Bone Neoplasms; Breast Neoplasms; Combined Modality Therapy; Denosum

2020
A case of resistant hypercalcemia of malignancy with a proposed treatment algorithm.
    The Annals of pharmacotherapy, 2009, Volume: 43, Issue:9

    Topics: Aged; Algorithms; Bone Density Conservation Agents; Calcitonin; Carcinoma, Transitional Cell; Crysta

2009
Osteonecrosis of the jaw: dental outcomes in metastatic breast cancer patients treated with bisphosphonates with/without bevacizumab.
    Clinical breast cancer, 2011, Volume: 11, Issue:4

    Topics: Adult; Aged; Angiogenesis Inhibitors; Anti-Bacterial Agents; Antibodies, Monoclonal, Humanized; Anti

2011
Pamidronate prevents the development of skeletal metastasis in nude mice transplanted with human breast cancer cells by reducing tumor burden within bone.
    International journal of oncology, 2003, Volume: 22, Issue:4

    Topics: Animals; Antineoplastic Agents; Bone and Bones; Bone Neoplasms; Calcium; Cell Line, Tumor; Creatinin

2003
Zoledronate in a patient with pamidronate refractory hypercalcemia syndrome.
    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2004, Volume: 12, Issue:9

    Topics: Bone Resorption; Breast Neoplasms; Diphosphonates; Drug Resistance; Female; Humans; Hypercalcemia; I

2004
Cost-effectiveness of oral ibandronate compared with intravenous (i.v.) zoledronic acid or i.v. generic pamidronate in breast cancer patients with metastatic bone disease undergoing i.v. chemotherapy.
    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2005, Volume: 13, Issue:12

    Topics: Administration, Oral; Bone Neoplasms; Breast Neoplasms; Clinical Trials, Phase III as Topic; Cohort

2005
Off-trial evaluation of bisphosphonates in patients with metastatic breast cancer.
    BMC cancer, 2005, Jul-28, Volume: 5

    Topics: Aged; Bone Diseases; Bone Neoplasms; Breast Neoplasms; Clinical Trials as Topic; Diphosphonates; Dis

2005
Skeletal retention of bisphosphonate (pamidronate) and its relation to the rate of bone resorption in patients with breast cancer and bone metastases.
    Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 2005, Volume: 20, Issue:9

    Topics: Aged; Alkaline Phosphatase; Bone and Bones; Bone Density Conservation Agents; Bone Neoplasms; Bone R

2005
Nephrotic-range proteinuria following pamidronate therapy in a patient with metastatic breast cancer: mitochondrial toxicity as a pathogenetic concept?
    American journal of kidney diseases : the official journal of the National Kidney Foundation, 2006, Volume: 47, Issue:6

    Topics: Antineoplastic Agents; Biopsy; Bone Neoplasms; Breast Neoplasms; Carcinoma, Ductal, Breast; Diphosph

2006
Bisphosphonates inhibit prostate and breast carcinoma cell adhesion to unmineralized and mineralized bone extracellular matrices.
    Cancer research, 1997, Sep-15, Volume: 57, Issue:18

    Topics: Bone Matrix; Bone Neoplasms; Breast Neoplasms; Calcification, Physiologic; Cell Adhesion; Cell Adhes

1997
Case of an ivory vertebra.
    Journal of endocrinological investigation, 2000, Volume: 23, Issue:8

    Topics: Alendronate; Alkaline Phosphatase; Biopsy; Bone Marrow; Carcinoid Tumor; Diagnosis, Differential; Di

2000
Testicular germ cell tumor with rhabdomyosarcoma successfully treated by disease-adapted chemotherapy including high-dose chemotherapy: case report and review of the literature.
    Bone marrow transplantation, 2001, Volume: 28, Issue:8

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carboplatin; Cell Differentiation; Cisp

2001
Distribution of 3-amino-1-hydroxypropane-1,1-diphosphonic acid in rats and effects on rat osteosarcoma.
    Arzneimittel-Forschung, 1985, Volume: 35, Issue:10

    Topics: Animals; Autoradiography; Bone Neoplasms; Diphosphonates; Electrolytes; Male; Neoplasm Metastasis; N

1985